Aldevron News

Genprex Taps Aldevron to Enable Full Commercial Scale Plasmid DNA Manufacturing Capabilities

Aldevron-Genprex-PartnerGenprex, Inc. (NASDAQ: GNPX), is collaborating with Aldevron to secure GMP plasmid DNA manufacturing capacity for Genprex's Oncoprex™ gene therapy portfolio.

The manufacturing program supports upcoming clinical trials, including Oncoprex™ in combination with Tagrisso®, which has received FDA Fast Track Designation. The collaboration with Aldevron will enable full commercial scale plasmid DNA manufacturing capabilities. 
The agreement represents an ongoing dedication to deliver best-in-class gene therapies to patients in need.

Topics: Gene Therapy, Plasmid DNA, Clinical Grade Manufacturing/cGMP, Partnerships